Dan Brennan
Stock Analyst at TD Cowen
(4.29)
# 431
Out of 4,623 analysts
99
Total ratings
60.24%
Success rate
12.18%
Average return
Main Sectors:
Stocks Rated by Dan Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $153 → $160 | $143.82 | +11.25% | 12 | Aug 22, 2024 | |
| ILMN Illumina | Upgrades: Buy | $126 → $144 | $145.54 | -1.06% | 11 | Aug 14, 2024 | |
| NTRA Natera | Maintains: Buy | $137 → $145 | $130.06 | +11.49% | 3 | Aug 9, 2024 | |
| GH Guardant Health | Maintains: Buy | $41 → $42 | $21.40 | +96.26% | 1 | Aug 8, 2024 | |
| CRL Charles River Laboratories International | Maintains: Buy | $290 → $240 | $192.97 | +24.37% | 4 | Aug 8, 2024 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $8.5 → $11 | $8.01 | +37.33% | 3 | Aug 8, 2024 | |
| MYGN Myriad Genetics | Maintains: Hold | $28 → $30 | $24.08 | +24.58% | 1 | Aug 7, 2024 | |
| WAT Waters | Maintains: Hold | $325 → $363 | $357.97 | +1.41% | 2 | Aug 1, 2024 | |
| WGS GeneDx Holdings | Maintains: Buy | $46 → $50 | $60.00 | -16.67% | 2 | Jul 31, 2024 | |
| RVTY Revvity | Maintains: Buy | $130 → $141 | $121.51 | +16.04% | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $24.75 | +25.25% | 3 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $648 → $658 | $596.92 | +10.23% | 12 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $270.33 | +14.67% | 4 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $51 | $43.00 | +18.60% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $295 → $300 | $229.26 | +30.86% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $48.82 | +2.42% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2.8 | $1.69 | +65.68% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $13.53 | +47.82% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $57 → $32 | $16.26 | +96.80% | 4 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $545 → $546 | $278.25 | +96.23% | 4 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.00 | +250.00% | 1 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 → $15 | $1.98 | +657.58% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $76 | $70.96 | +7.10% | 4 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $207 → $232 | $296.65 | -21.79% | 6 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $770 → $880 | $1,450.95 | -39.35% | 3 | Oct 7, 2020 |
Agilent Technologies
Aug 22, 2024
Maintains: Buy
Price Target: $153 → $160
Current: $143.82
Upside: +11.25%
Illumina
Aug 14, 2024
Upgrades: Buy
Price Target: $126 → $144
Current: $145.54
Upside: -1.06%
Natera
Aug 9, 2024
Maintains: Buy
Price Target: $137 → $145
Current: $130.06
Upside: +11.49%
Guardant Health
Aug 8, 2024
Maintains: Buy
Price Target: $41 → $42
Current: $21.40
Upside: +96.26%
Charles River Laboratories International
Aug 8, 2024
Maintains: Buy
Price Target: $290 → $240
Current: $192.97
Upside: +24.37%
Maravai LifeSciences Holdings
Aug 8, 2024
Maintains: Neutral
Price Target: $8.5 → $11
Current: $8.01
Upside: +37.33%
Myriad Genetics
Aug 7, 2024
Maintains: Hold
Price Target: $28 → $30
Current: $24.08
Upside: +24.58%
Waters
Aug 1, 2024
Maintains: Hold
Price Target: $325 → $363
Current: $357.97
Upside: +1.41%
GeneDx Holdings
Jul 31, 2024
Maintains: Buy
Price Target: $46 → $50
Current: $60.00
Upside: -16.67%
Revvity
Jul 30, 2024
Maintains: Buy
Price Target: $130 → $141
Current: $121.51
Upside: +16.04%
Jul 29, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $24.75
Upside: +25.25%
Jul 25, 2024
Maintains: Buy
Price Target: $648 → $658
Current: $596.92
Upside: +10.23%
Jul 24, 2024
Maintains: Buy
Price Target: $290 → $310
Current: $270.33
Upside: +14.67%
Jul 23, 2024
Maintains: Buy
Price Target: $48 → $51
Current: $43.00
Upside: +18.60%
Jul 23, 2024
Maintains: Buy
Price Target: $295 → $300
Current: $229.26
Upside: +30.86%
Jul 9, 2024
Initiates: Buy
Price Target: $50
Current: $48.82
Upside: +2.42%
May 13, 2024
Initiates: Buy
Price Target: $2.8
Current: $1.69
Upside: +65.68%
May 1, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $13.53
Upside: +47.82%
May 1, 2024
Downgrades: Hold
Price Target: $57 → $32
Current: $16.26
Upside: +96.80%
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $278.25
Upside: +96.23%
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $2.00
Upside: +250.00%
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.98
Upside: +657.58%
Feb 22, 2023
Maintains: Outperform
Price Target: $56 → $76
Current: $70.96
Upside: +7.10%
Mar 1, 2021
Upgrades: Buy
Price Target: $207 → $232
Current: $296.65
Upside: -21.79%
Oct 7, 2020
Downgrades: Sell
Price Target: $770 → $880
Current: $1,450.95
Upside: -39.35%